BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Peptide inhibitor of LY96 for ischemic and hemorrhagic stroke

By Claire Quang, Staff Writer
July 30, 2021 5:12 PM UTC

DISEASE CATEGORY: Neurology

INDICATION: Stroke...

BCIQ Company Profiles

Capital Medical University

Fourth Military Medical University

Tongji University

BCIQ Target Profiles

Cold inducible RNA binding protein (CIRP)

HIV tat protein (HIV tat)

Lymphocyte antigen 96 (LY96) (MD2)

BCIQ Company Profiles

Capital Medical University

Fourth Military Medical University

Tongji University

BCIQ Target Profiles

Cold inducible RNA binding protein (CIRP)

HIV tat protein (HIV tat)

Lymphocyte antigen 96 (LY96) (MD2)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS